Fovea Pharmaceuticals SA: Clinical Trials

4 trials sponsored by Fovea Pharmaceuticals SA, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

3 completed, 1 terminated. 3 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	3	Completed 3
Phase 1	1	Terminated 1

Follow Fovea Pharmaceuticals SA: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Safety and Efficacy Study of Topical Administration of FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy 2304 Eye Drops High Dose, 2304 Eye Drops Low Dose, Placebo Eye Drops - Diabetic Macular Edema	Phase 2	Completed	Fovea Pharmaceuticals SA	267	2011-05-01	2012-08-23
Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis CsA high dose, CsA low dose, PA - Allergic Conjunctivitis	Phase 2	Completed	Fovea Pharmaceuticals SA	716	2010-05-01	2012-03-09
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion FOV2302 (Ecallantide) - Macular Edema, Central Retinal Vein Occlusion	Phase 1	Terminated	Fovea Pharmaceuticals SA	11	2009-09-01	2012-01-10
Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®) - Allergic Conjunctivitis	Phase 2	Completed	Fovea Pharmaceuticals SA	155	2009-01-01	2012-03-09

Conditions studied

Interventions

Countries

Top investigators